Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of doxorubicin-induced cardiotoxicity in breast cancer
IRCT20250526065902N2Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in breast cancer (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Changes in echocardiographic patterns in strain echocardiography. Started Oct 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20250526065902N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250526065902N2.